KR20230015348A - Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물 - Google Patents

Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물 Download PDF

Info

Publication number
KR20230015348A
KR20230015348A KR1020227040648A KR20227040648A KR20230015348A KR 20230015348 A KR20230015348 A KR 20230015348A KR 1020227040648 A KR1020227040648 A KR 1020227040648A KR 20227040648 A KR20227040648 A KR 20227040648A KR 20230015348 A KR20230015348 A KR 20230015348A
Authority
KR
South Korea
Prior art keywords
ser
cells
val
thr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227040648A
Other languages
English (en)
Korean (ko)
Inventor
다스쿠 혼조
아키오 오타
마사키 다지마
하루히코 가마다
사토시 나가타
겐스케 스즈키
유야 오시로
요스케 도쿠마루
Original Assignee
고에키 자이단 호징 고베 이료 산교 도시 스이신 기코
고쿠리츠 켄큐 카이하츠 호진 이야쿠 키반 켄코 에이요 켄큐쇼
메이지 세이카 파루마 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고에키 자이단 호징 고베 이료 산교 도시 스이신 기코, 고쿠리츠 켄큐 카이하츠 호진 이야쿠 키반 켄코 에이요 켄큐쇼, 메이지 세이카 파루마 가부시키가이샤 filed Critical 고에키 자이단 호징 고베 이료 산교 도시 스이신 기코
Publication of KR20230015348A publication Critical patent/KR20230015348A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020227040648A 2020-05-25 2021-05-24 Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물 Pending KR20230015348A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020090526 2020-05-25
JPJP-P-2020-090526 2020-05-25
PCT/JP2021/019676 WO2021241523A1 (ja) 2020-05-25 2021-05-24 Ｔｈ２介在性疾患を治療または予防するためのＰＤ－１アゴニスト含有医薬組成物

Publications (1)

Publication Number Publication Date
KR20230015348A true KR20230015348A (ko) 2023-01-31

Family

ID=78744780

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227040648A Pending KR20230015348A (ko) 2020-05-25 2021-05-24 Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물

Country Status (7)

Country Link
US (1) US20230183347A1 (https=)
EP (1) EP4159235A4 (https=)
JP (1) JP7754455B2 (https=)
KR (1) KR20230015348A (https=)
CN (1) CN115697405A (https=)
TW (1) TWI890796B (https=)
WO (1) WO2021241523A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220596A (es) 2020-05-26 2023-01-23 Boehringer Ingelheim Int Anticuerpos anti-pd-1
WO2022239820A1 (ja) * 2021-05-13 2022-11-17 公益財団法人神戸医療産業都市推進機構 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物
KR20240137086A (ko) * 2022-01-28 2024-09-19 조지아뮨 인코포레이티드 Pd-1 작용제인 세포예정사 단백질 1에 대한 항체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2893855T3 (es) 2011-08-11 2022-02-10 Ono Pharmaceutical Co Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
CN107149530A (zh) * 2016-03-04 2017-09-12 吴东 一种洗头装置
MX2019002867A (es) 2016-09-19 2019-11-12 Celgene Corp Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
CN107149680A (zh) 2017-04-27 2017-09-12 中山大学 Pd‑1h激动剂在哮喘治疗中的应用
CN106924718A (zh) 2017-04-27 2017-07-07 中山大学 B7‑dc突变体在治疗哮喘中的应用
AR114127A1 (es) * 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
WO2022239820A1 (ja) * 2021-05-13 2022-11-17 公益財団法人神戸医療産業都市推進機構 炎症性疾患を治療又は予防するための抗ヒトｐｄ－１アゴニスト抗体及びこれを含有する医薬組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat. Immunol. 14:1212-8 (2013).
Young A, Quandt Z, Bluestone JA. The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunol. Res. 6:1445-1452 (2018).

Also Published As

Publication number Publication date
US20230183347A1 (en) 2023-06-15
TW202210099A (zh) 2022-03-16
CN115697405A (zh) 2023-02-03
EP4159235A1 (en) 2023-04-05
TWI890796B (zh) 2025-07-21
EP4159235A4 (en) 2024-07-10
JPWO2021241523A1 (https=) 2021-12-02
JP7754455B2 (ja) 2025-10-15
WO2021241523A1 (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
TWI851650B (zh) Ｇｐｒｃ５ｄ嵌合抗原受體及表現其之細胞
CA2951885C (en) Use of vista agonists and antagonists to suppress or enhance humoral immunity
CN111094350B (zh) 调节由细胞表达的生物活性的抗体
JP7148414B2 (ja) Ｐｄ－ｌ１特異的抗体およびそれを使用する方法
CN106939049B (zh) 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
JP2021508676A (ja) 抗ｔｉｇｉｔ抗体並びに治療剤及び診断剤としてのその使用
RU2650756C2 (ru) Антитела к h7cr
JP2020515239A (ja) 抗ｉｃｏｓアゴニスト抗体およびそれらの使用
JP2018502044A (ja) 抗ｐｄ−１抗体およびその用途
US20040092718A1 (en) Use of a CD28 binding substance for making a pharmaceutical composition
CN110546162A (zh) 用于增强肿瘤微环境中免疫应答的治疗剂和方法
IL297916A (en) Compositions and methods for tcr reprogramming using CD70-specific fusion proteins
KR20230015348A (ko) Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물
KR20190066067A (ko) 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
JP2025526677A (ja) Ｂ７－ｈ３抗原結合性分子
TW202317640A (zh) 一種抗人pd-l1人源化抗體或其抗原結合片段及其應用
US20250215089A1 (en) Antigen-binding protein targeting pd-l1 and cd40, preparation therefor, and use thereof
TWI790193B (zh) 調控免疫反應之方法及抗體
TW202540189A (zh) 在組合療法中能夠結合ｏｘ４０之抗體
KR20230154315A (ko) 항체의 신규한 조합물 및 이의 용도
HK40110611A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
JP2026513865A (ja) がんを処置するためのｐｄ－ｌ１およびｃｄ１３７に対する多重特異性結合剤
Ryan Improving Combination Cancer Immunotherapy with a Novel, Dual-Specific Immunotherapeutic Platform that Links T Cell Costimulatory Pathways

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902